Chart of the Day: Perfect Timing on Our Robotics ETF
We recently added this group as investors think about SpaceX and growth in the sector.
Why We’re Keeping Our $700 Price Target on This Holding as Shares Drop
Let’s break down the latest earnings and guidance, why the stock’s moving lower today and our plan going forward.
I’m Eyeing 2 Biopharma Stocks Amid Choppy Market Action
These small-cap biotechs offer core businesses that fund a much bigger opportunity.
Inseego Reports, and My Question Is: What Was I Thinking?!
Here’s how I’m handling this holding after a dismal report … and why I’m adding to another name that has the right ‘ingredients.’
Meta Joins OpenAI, Anthropic With High-Profile Hack: 8 Key Items Shaping the Stock Market Thursday
SpaceX IPO lockup expiration begins, Fed blowback and other headlines moving stocks this morning.
Market Indecision: War Uncertainty, Wacky Econ Data, Fake News?
Investors are stuck dealing with more questions over the state of the Strait, economic data that doesn’t quite make sense, and accusations of fake news.
New Arista Network Price Target After $2.1 Billion Projection Boost
Demand continues to climb, but supply chain woes look to slow that conversation to revenue and earnings.
Chart of the Day: Palantir Flips the Script
The stock had a monster move up after earnings and looks to find more upside ahead.
VIDEO: Why SpaceX Is Falling Despite Earnings BeatÂ
And why retail earnings could be more of a challenge for the market.
I See Two Very Different Opportunities in This Overbought Market
I’m getting into a legacy technology stock and an up-and-coming biopharma. Here’s why.